title: FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features.
abstract: 2-[Fluorine-18]fluoro-2-deoxy-d-glucose (FDG) uptake within the primary lesion correlates with survival on positron emission tomography (PET) studies of patients with non-small cell lung cancer. The more metabolically active the tumour, the worse the outcome. The aim of this study was to determine whether a correlation exists between aggressiveness as determined by pathology and the findings of FDG PET in pulmonary adenocarcinoma. Thirty-five patients with 38 adenocarcinomas of the lung were studied. All patients underwent thoracotomy within 4 weeks of the FDG PET study. For semiquantitative analysis, standardized uptake values (SUVs) were calculated. Patients were classified into high SUV (> or = 4.0) and low SUV (<4.0) groups. The degree of FDG uptake (SUVs) in primary lung lesions was correlated with the histopathological features of aggressiveness (pleural involvement, vascular invasion or lymphatic permeation). The mean SUV of aggressive adenocarcinomas (4.36+/-1.94, n = 22) was higher than that of non-aggressive ones (1.53+/-0.88, n = 16) (P < 0.0001). Tumours with a high FDG uptake have a significantly higher likelihood of aggressiveness than those with a low FDG uptake (P = 0.0004). Analysis by the Kaplan-Meier methods revealed that the groups had different prognoses (log-rank test, P = 0.0099). The high SUV group had a significantly worse prognosis. In conclusion, a correlation was seen between aggressiveness as determined by pathology and glucose metabolism as measured by FDG PET in adenocarcinoma of the lung. FDG PET may be used as a non-invasive diagnostic technique in measuring aggressiveness and prognosis in patients with pulmonary adenocarcinoma.
authors.affiliation: Department of Radiology, Kanazawa Medical University, Japan. h550208@kanazawa-med.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Higashi
authors.forename: Y
authors.initials: Y
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Ayabe
authors.forename: A
authors.initials: A
authors.lastname: Sakurai
authors.forename: H
authors.initials: H
authors.lastname: Seki
authors.forename: Y
authors.initials: Y
authors.lastname: Nambu
authors.forename: M
authors.initials: M
authors.lastname: Oguchi
authors.forename: H
authors.initials: H
authors.lastname: Shikata
authors.forename: S
authors.initials: S
authors.lastname: Taki
authors.forename: H
authors.initials: H
authors.lastname: Tonami
authors.forename: S
authors.initials: S
authors.lastname: Katsuda
authors.forename: I
authors.initials: I
authors.lastname: Yamamoto
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology*; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D016019:Survival Analysis
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose